[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342895-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342895-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tpx2-overexpression-promotes-sensitivity-to-dasatinib-in-breast-cancer-by-activating-yap-transcriptional-signaling","TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling","","TPX2 overexpression is shown to increase breast cancer sensitivity to the SRC inhibitor dasatinib by activating the YAP transcriptional signaling pathway. The work links chromosomal instability (CIN) to cancer aggressiveness, noting that CIN-positive tumors overexpress mitotic regulators and show poor prognosis. A drug screening strategy using inducible CIN-associated gene expression identifies TPX2 and YAP activation as drivers, while TCGA and patient-cohort analyses associate them with reduced outcomes, supporting their use as dasatinib selection biomarkers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tpx2-overexpression-promotes-sensitivity-to-dasatinib-in-breast-cancer-by-activating-yap-transcriptional-signaling/342895/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tpx2-overexpression-promotes-sensitivity-to-dasatinib-in-breast-cancer-by-activating-yap-transcriptional-signaling/342895.png","ImageObject",300,407,{"name":42,"@type":43},"Violet","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main finding about TPX2 and dasatinib sensitivity?","Question",{"text":63,"@type":64},"TPX2 overexpression enhances breast cancer sensitivity to dasatinib by activating YAP transcriptional signaling through the SRC-related mechanism.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is chromosomal instability (CIN) considered important for therapy?",{"text":68,"@type":64},"CIN is associated with aggressiveness and poor prognosis, and it is uncommon in healthy tissues, creating a therapeutic window where CIN-targeting may spare normal cells.",{"name":70,"@type":61,"acceptedAnswer":71},"How is the clinical relevance of TPX2 and YAP activation supported?",{"text":72,"@type":64},"Analysis of breast cancer data from TCGA and a patient-derived cohort shows TPX2 overexpression and YAP activation occur in a significant subset of tumors and correlate with poor prognosis, indicating biomarker potential for selecting dasatinib therapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342895,1790174457,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling  \nCarlos Marugn 1,2 , Natalia Sanz-Gmez 1 , Beatriz Ortigosa 1,3, Ana Monfort-Vengut 1 , Cristina Bertinetti 1, Ana Teijo4, Marta Gonzlez 1, Alicia Alonso de la Vega 1 , Mar a Jos Lallena2, Gema Moreno-Bueno3,5,6,7  and Guillermo de Crcer 1,7   \n1 Cell Cycle & Cancer Biomarkers Laboratory, Cancer Department, Instituto de Investigaciones Biomdicas Sols-Morreale (IIBM) CSIC-UAM, Madrid, Spain  \n2 Discovery Chemistry Research and Technology, Eli Lilly and Company, Madrid, Spain  \n3 Translational Cancer Research Laboratory, Cancer Department, Instituto de Investigaciones Biomdicas Alberto Sols-Morreale (IIBM) CSIC-UAM, Madrid, Spain  \n4 Pathology Department, MD Anderson Cancer Center, Madrid, Spain  \n5 MD Anderson International Foundation, Madrid, Spain  \n6 Biomedical Cancer Research Network (CIBERONC), Madrid, Spain  \n7 CSIC Conexin-Cncer Hub ([https://conexion-cancer.csic.es](https://conexion-cancer.csic.es)),  \nKeywords  \nchromosomal instability; dasatinib; HippoYAP/TAZ; mitosis; SFK kinases; TPX2  \nCorrespondence  \nG. de Crcer, Cell Cycle & Cancer Biomarkers Laboratory, Cancer Department, Instituto de Investigaciones Biomdicas Sols-Morreale (IIBM) CSIC-UAM, Madrid 28029, Spain  \nE-mail: [gdecarcer@iib.uam.es](gdecarcer@iib.uam.es)  \nCarlos Marug-Gmez contributed equally to this article.  \n(Received 11 September 2023, revised 3 January 2024, accepted 26 January 2024, available online 15 February 2024)  \ndoi:10 . 1002/1878-0261 .13602  \nChromosomal instability (CIN) is a hallmark of cancer aggressiveness, providing genetic plasticity and tumor heterogeneity that allows the tumor to evolve and adapt to stress conditions. CIN is considered a cancer therapeutic biomarker because healthy cells do not exhibit CIN. Despite recent efforts to identify therapeutic strategies related to CIN, the results obtained have been very limited. CIN is characterized by a genetic signature where a collection of genes, mostly mitotic regulators, are overexpressed in CINpositive tumors, providing aggressiveness and poor prognosis. We attempted to identify new therapeutic strategies related to CIN genes by performing a drug screen, using cells that individually express CINassociated genes in an inducible manner. We ﬁnd that the overexpression of targeting protein for Xklp2 (TPX2) enhances sensitivity to the protooncogene c-Src (SRC) inhibitor dasatinib due to activation of the Yesassociated protein 1 (YAP) pathway. Furthermore, using breast cancer data from The Cancer Genome Atlas (TCGA) and a cohort of cancerderived patient samples, we ﬁnd that both TPX2 overexpression and YAP activation are present in a signiﬁcant percentage of cancer tumor samples and are associated with poor prognosis; therefore, they are putative biomarkers for selection for dasatinib therapy.  \nAbbreviations  \nANOVA, analysis of variance; AUC, area under the curve; CIN, chromosomal instability; CNA, copy number alteration; CRC, concentrationresponse curves; CTRP, cancer therapeutics response portal; DAPI, 40 ,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; DOX, doxycycline; DPBQ, 8-azaguanine and 2,3-diphenylbenzo[g]quinoxaline-5,10-dione; EDTA, ethylenediaminetetraacetic acid; ER, estrogen receptor; FDR, false discovery rate; GSEA, gene set enrichment analysis; HER2, human epidermal growth factor receptor 2; HR, homologous recombination; IHC, immunohistochemistry; METABRIC, Molecular Taxonomy of Breast Cancer International Consortium; NCCN, National Comprehensive Cancer Network; NES, normalized enrichment score; NHEJ, non-homologous end joining; NIH, National Institutes of Health; PBS, phosphate-buffered saline buffer; qRT-PCR, real-time quantitative reverse transcription PCR; RF, relapse free; RIPA, radioimmunoprecipitation assay buffer; rtTA, reverse transcriptional activator; SDS, sodium dodecyl sulfate; SFK, SRC family kinases; TCGA, The Cancer Genome Atla","cbCail7B4FwqXFHW","https://ap.wps.com/l/cbCail7B4FwqXFHW","pdf",9068432,21,"English","# Introduction\n## Chromosomal instability (CIN) as a cancer hallmark\n## Therapeutic opportunity and drug-sensitivity links\n# Abstract and key findings\n## TPX2-driven YAP activation enhances dasatinib sensitivity\n## Prognostic relevance from TCGA and patient cohorts","[{\"question\":\"What is the main finding about TPX2 and dasatinib sensitivity?\",\"answer\":\"TPX2 overexpression enhances breast cancer sensitivity to dasatinib by activating YAP transcriptional signaling through the SRC-related mechanism.\"},{\"question\":\"Why is chromosomal instability (CIN) considered important for therapy?\",\"answer\":\"CIN is associated with aggressiveness and poor prognosis, and it is uncommon in healthy tissues, creating a therapeutic window where CIN-targeting may spare normal cells.\"},{\"question\":\"How is the clinical relevance of TPX2 and YAP activation supported?\",\"answer\":\"Analysis of breast cancer data from TCGA and a patient-derived cohort shows TPX2 overexpression and YAP activation occur in a significant subset of tumors and correlate with poor prognosis, indicating biomarker potential for selecting dasatinib therapy.\"}]","TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling | PDF",1790048700,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/691d7481463fca946366cf4db7c6a6f0.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef36aa5133c8566a2b25c9a5c0365c17.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c52650257dd042257d2047b4b2b4946.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ffd158887aea1a8adad2dd57bd434a3.webp",980,1287]